← Ticker index
CI
Ticker
CI
The Cigna Group
HOSPITAL & MEDICAL SERVICE PLANS
Congressional Trades
114
by 10 members
Ticker disclosure brief
Congressional disclosure records for CI
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
SELL · 2026-06-02
Largest range
$15K – $50K
Ro Khanna
Longest observed gap
318d
Valerie Hoyle
Highest 30d vs SPY
13.1%
Ro Khanna
Purchase rows
49
43%
Sale rows
65
57%
Disclosed midpoint
$1.2M
range estimate
Unique Traders
10
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats97 · 85%
Republicans17 · 15%
Lobbying filings
all →- 2026-04-21$50KCIGNAPharmacy issues related to TRICARE. Issues surrounding pharmacy benefit managers, and coverage of biosimilars.
- 2026-04-20$3.5MTHE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)Issues related to prior authorization; ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model Issues relating to implementation of the No Surprises Act H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act Issues related to competition in the health care marketplace.
- 2026-04-20$1.7MTHE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)Issues related to prior authorization. S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act. H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026. "S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency. Issues related to competition in the health care marketplace.
- 2026-04-20$90KCIGNA CORPORATION AND SUBSIDIARIESIssues related to pharmacy and prescription drug pricing; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the extension of Enhanced Advanced Premium Tax Credits (EAPTCs) in the American Rescue Plan Act (PL 117-2) and the Inflation Reduction Act (PL 117-169); Issues relating to implementation of the No Surprises Act (PL 116-260). Pharmacy issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60). Issues related to H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
- 2026-04-20$60KTHE CIGNA GROUP AND SUBSIDIARIESIssues related to commercial insurance and pharmacy benefits. H.R.4710: No Surprises Act. H.R.7895: PBM Kickback Prohibition Act.
- 2026-04-19$20KTHE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES)Pharmacy issues related to TRICARE; FY2027 Department of Defense Appropriations, FY2027 National Defense Authorization Act Issues related to P.L. 116-260, the No Surprises Act
- 2026-04-17$90KCIGNA CORPORATIONEducate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; and proposals related to telehealth. Monitor pharmacy issues related to TRICARE.
- 2026-04-17$90KCIGNA CORPORATIONProvide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues Drug pricing and issues facing the pharmacy benefit manager industry generally
- 2026-04-17$50KCIGNA CORPORATE SERVICES LLC AND ITS AFFILIATESIssues related to health care policy including coverage and cost of care.
- 2026-04-16$0THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Loading trade analytics…
All Disclosed Trades
Page 1 · 25 of 114 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2026-06-02 | DRo Khanna | SELL | $15K – $50K | 34d | receipt → |
| 2026-05-15 | DRo Khanna | BUY | $1K – $15K | 25d | receipt → |
| 2026-04-13 | DRo Khanna | SELL | $15K – $50K | 28d | receipt → |
| 2026-04-13 | DRo Khanna | SELL | $15K – $50K | 28d | receipt → |
| 2026-04-24 | DRo Khanna | SELL | $1K – $15K | 17d | receipt → |
| 2026-04-24 | DRo Khanna | SELL | $1K – $15K | 17d | receipt → |
| 2026-03-23 | DJared Moskowitz | SELL | $1K – $15K | 39d | receipt → |
| 2026-03-23 | DJared Moskowitz | SELL | $1K – $15K | 39d | receipt → |
| 2026-03-23 | DJared Moskowitz | SELL | $1K – $15K | 38d | receipt → |
| 2026-03-23 | DJared Moskowitz | SELL | $1K – $15K | 38d | receipt → |
| 2026-03-13 | DGilbert Cisneros | SELL | $1K – $15K | 26d | receipt → |
| 2026-03-13 | DGilbert Cisneros | SELL | $1K – $15K | 26d | receipt → |
| 2026-03-13 | DGilbert Cisneros | SELL | $1K – $15K | 25d | receipt → |
| 2026-03-13 | DGilbert Cisneros | SELL | $1K – $15K | 25d | receipt → |
| 2026-02-24 | DRo Khanna | BUY | $1K – $15K | 13d | receipt → |
| 2026-02-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2026-02-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2026-02-24 | DRo Khanna | BUY | $1K – $15K | 13d | receipt → |
| 2026-01-29 | DRo Khanna | BUY | $15K – $50K | 8d | receipt → |
| 2026-01-13 | DRo Khanna | BUY | $1K – $15K | 24d | receipt → |
| 2026-01-13 | DRo Khanna | BUY | $1K – $15K | 24d | receipt → |
| 2025-12-18 | DJulie Johnson | SELL | $1K – $15K | 29d | receipt → |
| 2025-12-18 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-12-18 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-04-22 | RJulia Letlow | SELL | $1K – $15K | 267dApparent delay | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.